Ambarella Inc: Form 10-Q for the period ended Oct 31, 2024
Filed with the SEC on Dec 6, 2024 and accepted by EDGAR at Dec 6, 2024, 15:20 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-08-01 to 2024-10-31 | $82.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-02-01 to 2024-10-31 | $200.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-08-01 to 2024-10-31 | $32.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-02-01 to 2024-10-31 | $78.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-08-01 to 2024-10-31 | $50.0m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-02-01 to 2024-10-31 | $121.9m | us-gaap:GrossProfit |
| Research and development | 3 months2024-08-01 to 2024-10-31 | $58.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-02-01 to 2024-10-31 | $169.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-08-01 to 2024-10-31 | $17.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-02-01 to 2024-10-31 | $53.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-08-01 to 2024-10-31 | −$25.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-02-01 to 2024-10-31 | −$101.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-08-01 to 2024-10-31 | $652.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-02-01 to 2024-10-31 | $2.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-08-01 to 2024-10-31 | −$24.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-02-01 to 2024-10-31 | −$96.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-08-01 to 2024-10-31 | −$0.58 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-02-01 to 2024-10-31 | −$2.36 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-08-01 to 2024-10-31 | −$0.58 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-02-01 to 2024-10-31 | −$2.36 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-08-01 to 2024-10-31 | 41,479,459 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-02-01 to 2024-10-31 | 41,128,068 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-02-01 to 2024-10-31 | $8.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-02-01 to 2024-10-31 | $6.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2024-10-31 | $127.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-10-31 | $303.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-10-31 | $670.8m | us-gaap:Assets |
| Current liabilities | At period end2024-10-31 | $106.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-10-31 | $116.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-10-31 | $554.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-134023. Last ingested by Listed: Oct 30, 2026, 13:39 ET. Listed shows no prices and gives no investment advice.